SG11201804197RA - T7 alpha viral vector system - Google Patents
T7 alpha viral vector systemInfo
- Publication number
- SG11201804197RA SG11201804197RA SG11201804197RA SG11201804197RA SG11201804197RA SG 11201804197R A SG11201804197R A SG 11201804197RA SG 11201804197R A SG11201804197R A SG 11201804197RA SG 11201804197R A SG11201804197R A SG 11201804197RA SG 11201804197R A SG11201804197R A SG 11201804197RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- pct
- applicant
- publication
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36151—Methods of production or purification of viral material
- C12N2770/36152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10211—Podoviridae
- C12N2795/10222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Developmental Biology & Embryology (AREA)
- Transplantation (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property - Organization International Bureau Sd ... ...... ..r .„,\" (43) International Publication Date 26 May 2017(26.05.2017) WIPO I PCT (10) WO International 111111111111311111111111111111111111111111111111111111111111111111111311111111111111111 2017/087763 Publication Al Number (51) International Patent Classification: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, C12N 15/86 (2006.01) Cl 2N 5/074 (2010.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, C12N 7/02 (2006.01) C12N 5/071 (2010.01) KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW SA, PCT/US2016/062703 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (22) International Filing Date: TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 18 November 2016 (18.11.2016) ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (30) Priority Data: TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 62/256,788 18 November 2015 (18.11.2015) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicant: ORBIS HEALTH SOLUTIONS LLC LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, [US/US]; 111 Smith Hines Road, Suites E&F, Greenville, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, South Carolina 29607 (US). GW, KM, ML, MR, NE, SN, TD, TG). (72) Inventor: WAGNER, Thomas E.; 104 Golden Wings Declarations under Rule 4.17: Way, Greenville, South Carolina 29650 (US). — as to applicant's entitlement to apply for and be granted a (74) Agents: SCHORR, Kristel et al.; Foley & Lardner LLP, patent (Rule 4.170) 3000 K Street NW, Suite 600, Washington, District of as to the applicant's entitlement to claim the priority of the Columbia 20007 (US). earlier application (Rule 4.17 (iii)) Designated States indicated, (81) (unless otherwise for every Published: kind of national available): AE, AG, AL, AM, protection AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, — with international search report (Art 21(3)) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, [Continued on next page] Title: T7 ALPHA VIRAL VECTOR SYSTEM (54) Figure 1 A 17 terminator H E FP rigin ‘,. RES , i prom E -' V -- 17 prom r 7/NS P 1- 4/HygEGFP pT , 17.mines: z.gss :h 5 1-1 .41 en IN IN GC ------------------. o nspl -4 IN 1-1 (57) : The present invention relates generally to a gene expression system utilizing an alphavirus replicon and T7 promoter. N The system is capable of expressing proteins in the cell cytoplasm without integrating the gene of interest into the genome of a host cell. The invention has a wide range of applications such as producing induced pluripotent cells and vaccines against pathogens and 0 cancers. WO 2017/087763 Al 111M110111101110111111111111111110111111111111111111111111011111111011110111111 — before the expiration of the time limit for amending the claims and amendments to be (Rule republished 48.2(h)) in the event of receipt of
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562256788P | 2015-11-18 | 2015-11-18 | |
PCT/US2016/062703 WO2017087763A1 (en) | 2015-11-18 | 2016-11-18 | T7 alpha viral vector system |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201804197RA true SG11201804197RA (en) | 2018-06-28 |
Family
ID=58717836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201804197RA SG11201804197RA (en) | 2015-11-18 | 2016-11-18 | T7 alpha viral vector system |
Country Status (8)
Country | Link |
---|---|
US (1) | US10801041B2 (en) |
EP (1) | EP3377635A4 (en) |
JP (1) | JP2019500025A (en) |
AU (1) | AU2016355191B2 (en) |
BR (1) | BR112018010006A2 (en) |
CA (1) | CA3005739A1 (en) |
SG (1) | SG11201804197RA (en) |
WO (1) | WO2017087763A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3681993A1 (en) * | 2017-09-13 | 2020-07-22 | BioNTech RNA Pharmaceuticals GmbH | Rna replicon for reprogramming somatic cells |
CN118512582A (en) | 2018-01-02 | 2024-08-20 | 克洛里斯生物科学有限公司 | IPSC-based vaccine as a prophylactic and therapeutic treatment for cancer |
WO2021138447A1 (en) | 2019-12-31 | 2021-07-08 | Elixirgen Therapeutics, Inc. | Temperature-based transient delivery of nucleic acids and proteins to cells and tissues |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0138854B1 (en) | 1983-03-08 | 1992-11-04 | Chiron Mimotopes Pty. Ltd. | Antigenically active amino acid sequences |
US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US4937190A (en) | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
EP0442926A1 (en) | 1988-11-10 | 1991-08-28 | Imperial Cancer Research Technology Limited | Polypeptides |
US5122457A (en) | 1989-10-19 | 1992-06-16 | Schering Corporation | Expression systems utilizing bacteriophage t7 promoters, gene sequences, and t7 rna polymerase |
DE69333433T2 (en) | 1992-04-01 | 2004-12-02 | The Rockefeller University | METHOD FOR THE VITRO CULTIVATION OF DENDRITIC PROCUREMENT CELLS AND THE USE THEREOF FOR IMMUNOGENOUS PRODUCTION |
US5788963A (en) | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
US5962318A (en) | 1996-11-15 | 1999-10-05 | St. Jude Children's Research Hospital | Cytotoxic T lymphocyte-mediated immunotherapy |
US6387888B1 (en) | 1998-09-30 | 2002-05-14 | American Foundation For Biological Research, Inc. | Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen |
CA2407050A1 (en) | 2000-04-25 | 2001-11-01 | Chiron Corporation | Alphavirus-based vectors for persistent infection |
AU2002242016A1 (en) * | 2001-02-01 | 2002-08-12 | The Johns Hopkins University | Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation |
US6875612B2 (en) * | 2001-03-30 | 2005-04-05 | Greenville Hospital System | Monocyte-specific particulate delivery vehicle |
US20040121165A1 (en) | 2002-12-20 | 2004-06-24 | Laird Ronald E. | Coated article with reduced color shift at high viewing angles |
EP1608762B1 (en) * | 2003-03-20 | 2014-01-08 | Alphavax, Inc. | Improved alphavirus replicons and helper constructs |
WO2006086838A1 (en) * | 2005-02-16 | 2006-08-24 | The Council Of The Queensland Institute Of Medical Research | Flavivirus replicon constructs for tumour therapy |
BRPI0619794B8 (en) | 2005-12-13 | 2022-06-14 | Univ Kyoto | Use of a reprogramming factor, agent for preparing an induced pluripotent stem cell from a somatic cell and methods for preparing an induced pluripotent stem cell method and for preparing a somatic cell and use of induced pluripotent stem cells |
SG193653A1 (en) | 2007-03-23 | 2013-10-30 | Wisconsin Alumni Res Found | Somatic cell reprogramming |
JP2010524507A (en) * | 2007-04-25 | 2010-07-22 | オービス・ヘルス・ソリューションズ | Macrophage transfection method |
WO2010037402A1 (en) * | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
EP2342333A4 (en) | 2008-10-30 | 2013-05-08 | Univ Kyoto | Method for producing induced pluripotent stem cells |
WO2010108126A2 (en) | 2009-03-19 | 2010-09-23 | Fate Therapeutics, Inc. | Reprogramming compositions and methods of using the same |
WO2011112414A2 (en) * | 2010-03-12 | 2011-09-15 | Lipo Chemicals Inc. | Compound, composition, and method for protecting skin from high energy visible light |
EP3449910A1 (en) * | 2010-07-06 | 2019-03-06 | GlaxoSmithKline Biologicals S.A. | Cationic oil-in-water emulsions |
EP2632486A1 (en) | 2010-10-27 | 2013-09-04 | Harrisvaccines Inc | Method of rapidly producing vaccines for animals |
SG11201407595UA (en) | 2012-05-21 | 2014-12-30 | Univerisity Of California | Generation of human ips cells by a synthetic self- replicative rna |
WO2013192144A2 (en) * | 2012-06-19 | 2013-12-27 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Rift valley fever virus replicon particles and use thereof |
-
2016
- 2016-11-18 JP JP2018525744A patent/JP2019500025A/en active Pending
- 2016-11-18 BR BR112018010006A patent/BR112018010006A2/en not_active Application Discontinuation
- 2016-11-18 WO PCT/US2016/062703 patent/WO2017087763A1/en active Application Filing
- 2016-11-18 EP EP16867199.8A patent/EP3377635A4/en not_active Withdrawn
- 2016-11-18 US US15/776,855 patent/US10801041B2/en active Active
- 2016-11-18 SG SG11201804197RA patent/SG11201804197RA/en unknown
- 2016-11-18 CA CA3005739A patent/CA3005739A1/en active Pending
- 2016-11-18 AU AU2016355191A patent/AU2016355191B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU2016355191B2 (en) | 2023-06-29 |
US20180371494A1 (en) | 2018-12-27 |
AU2016355191A1 (en) | 2018-06-14 |
CA3005739A1 (en) | 2017-05-26 |
EP3377635A4 (en) | 2019-05-08 |
US10801041B2 (en) | 2020-10-13 |
EP3377635A1 (en) | 2018-09-26 |
BR112018010006A2 (en) | 2019-02-05 |
WO2017087763A1 (en) | 2017-05-26 |
JP2019500025A (en) | 2019-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201909777YA (en) | Modulatory polynucleotides | |
SG11201804696RA (en) | Techniques for metadata processing | |
SG11201909868YA (en) | Compositions and methods of treating huntington's disease | |
SG11201807912SA (en) | Vaccine against rsv | |
SG11201900447SA (en) | Methods and compositions for modifying genomic dna | |
SG11201803983UA (en) | Transformable tagging compositions, methods, and processes incorporating same | |
SG11201807573VA (en) | Methods for providing single-stranded rna | |
SG11201901531TA (en) | Regulation of gene expression using engineered nucleases | |
SG11201805072PA (en) | Nicotine powder delivery system | |
SG11201901221YA (en) | Methods for detecting aav | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201908391XA (en) | Methods for modulating an immune response | |
SG11201909870SA (en) | Compositions and methods of treating amyotrophic lateral sclerosis (als) | |
SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
SG11201804729RA (en) | Methods and compositions for treating a serpinc1-associated disorder | |
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201809643UA (en) | Compositions and methods of treating huntington's disease | |
SG11201804411TA (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201809437TA (en) | Intracellular delivery of biomolecules to induce tolerance | |
SG11201804528YA (en) | Multi-passenger ride vehicle | |
SG11201903042VA (en) | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome | |
SG11201408124PA (en) | Differentiation of human embryonic stem cells into pancreatic endocrine cells | |
SG11201803169WA (en) | Cellulase variants and polynucleotides encoding same |